Brendan OConnell - BIOLASE Vice President - Finance and Corporate Controller
| BIOL Stock | USD 0.15 0.01 7.14% |
President
Mr. Brendan OConnell is a appointed as Vice President Finance and Corporationrationrate Controller in January 2015. Mr. OConnell began his career with Biolase as our Assistant Controller in May 2007 and was promoted to serve as our Corporationrationrate Controller effective February 2009 since 2015.
| Age | 38 |
| Tenure | 9 years |
| Professional Marks | MBA |
| Address | 27042 Towne Centre Drive, Foothill Ranch, CA, United States, 92610-2811 |
| Phone | 949 361 1200 |
| Web | https://www.biolase.com |
BIOLASE Management Efficiency
The company has return on total asset (ROA) of (0.2855) % which means that it has lost $0.2855 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.0283) %, meaning that it created substantial loss on money invested by shareholders. BIOLASE's management efficiency ratios could be used to measure how well BIOLASE manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is expected to rise to 87.71 this year, although the value of Return On Tangible Assets will most likely fall to (0.67). At this time, BIOLASE's Non Currrent Assets Other are quite stable compared to the past year. Other Current Assets is expected to rise to about 1.5 M this year, although the value of Non Current Assets Total will most likely fall to about 5.7 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Jeffrey Cunningham | HealthStream | 57 | |
| Ashley Dreier | HealthEquity | 44 | |
| Frode Jensen | HealthEquity | 64 | |
| William Otten | HealthEquity | 52 | |
| Jeffery Doster | HealthStream | 51 | |
| Delano Ladd | HealthEquity | 43 | |
| Michael Collier | HealthStream | 48 | |
| Thomas Schultz | HealthStream | 49 | |
| Jonathan Maack | Definitive Healthcare Corp | 45 | |
| Edward Pearson | HealthStream | 61 | |
| Larry Trittschuh | HealthEquity | 52 | |
| Mollie Condra | HealthStream | N/A | |
| Edward Bloomberg | HealthEquity | 41 | |
| Scott McQuigg | HealthStream | 50 | |
| Steven Jackson | National Research Corp | 42 | |
| Jonathan Soldan | HealthEquity | 32 | |
| Angelique Hill | HealthEquity | 55 | |
| Gary Robinson | HealthEquity | 55 | |
| Trisha Coady | HealthStream | 48 | |
| Kevin Karas | National Research Corp | 60 | |
| Michael Sousa | HealthStream | 55 | |
Management Performance
| Return On Equity | -6.03 | ||||
| Return On Asset | -0.29 |
BIOLASE Leadership Team
Elected by the shareholders, the BIOLASE's board of directors comprises two types of representatives: BIOLASE inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BIOLASE. The board's role is to monitor BIOLASE's management team and ensure that shareholders' interests are well served. BIOLASE's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BIOLASE's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brendan OConnell, Vice President - Finance and Corporate Controller | ||
| Richard Lanman, Director | ||
| James Talevich, Independent Director | ||
| Jonathan Lord, Director | ||
| Terence Kelly, Director | ||
| Holger Arens, Vice President Managing Director of Europe, the Middle East and Africa | ||
| Paul Clark, Independent Chairman of the Board | ||
| Tamar Howson, Director | ||
| Harold Flynn, CEO and President and Director | ||
| Jess Roper, Director | ||
| David Dreyer, CFO | ||
| Garrett Sato, Director | ||
| George Bickerstaff, Director | ||
| David Rodriguez, Director Events | ||
| Samuel Low, Vice President - Dental and Clinical Affairs, Chief Dental Officer | ||
| James Surek, Vice President - Sales, Americas | ||
| Matthew Wilson, Vice President of Human Resources | ||
| Todd Norbe, Director | ||
| Russell DDS, Chief Officer | ||
| Michael Carroll, Corporate Secretary | ||
| Steven Sandor, Chief Officer | ||
| Todd Kehrli, IR Contact Officer | ||
| Michael Polyviou, IR Contact Officer | ||
| Jennifer Bright, Chief Officer | ||
| Elaine Wagner, Director | ||
| Frederic Moll, Director | ||
| Michael Roux, Vice President of Marketing | ||
| John Beaver, CFO, Senior Vice President |
BIOLASE Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BIOLASE a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.03 | ||||
| Return On Asset | -0.29 | ||||
| Profit Margin | (0.42) % | ||||
| Operating Margin | (0.35) % | ||||
| Current Valuation | 16.22 M | ||||
| Shares Outstanding | 33.26 M | ||||
| Shares Owned By Insiders | 0.33 % | ||||
| Shares Owned By Institutions | 8.23 % | ||||
| Number Of Shares Shorted | 2.29 M | ||||
| Price To Earning | (7.23) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards BIOLASE in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, BIOLASE's short interest history, or implied volatility extrapolated from BIOLASE options trading.
Pair Trading with BIOLASE
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BIOLASE position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BIOLASE will appreciate offsetting losses from the drop in the long position's value.Moving together with BIOLASE Stock
| 0.71 | GH | Guardant Health Financial Report 14th of May 2024 | PairCorr |
Moving against BIOLASE Stock
| 0.85 | HQY | HealthEquity Financial Report 3rd of June 2024 | PairCorr |
| 0.74 | AGTI | Agiliti Sell-off Trend | PairCorr |
| 0.72 | RCM | R1 RCM Inc Financial Report 2nd of May 2024 | PairCorr |
| 0.7 | DHR | Danaher Buyout Trend | PairCorr |
| 0.62 | CERT | Certara Financial Report 13th of May 2024 | PairCorr |
The ability to find closely correlated positions to BIOLASE could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BIOLASE when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BIOLASE - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BIOLASE to buy it.
The correlation of BIOLASE is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BIOLASE moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BIOLASE moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BIOLASE can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BIOLASE. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. For more information on how to buy BIOLASE Stock please use our How to buy in BIOLASE Stock guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for BIOLASE Stock analysis
When running BIOLASE's price analysis, check to measure BIOLASE's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BIOLASE is operating at the current time. Most of BIOLASE's value examination focuses on studying past and present price action to predict the probability of BIOLASE's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BIOLASE's price. Additionally, you may evaluate how the addition of BIOLASE to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is BIOLASE's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BIOLASE. If investors know BIOLASE will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BIOLASE listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (29.44) | Revenue Per Share 38.469 | Quarterly Revenue Growth (0.04) | Return On Assets (0.29) | Return On Equity (6.03) |
The market value of BIOLASE is measured differently than its book value, which is the value of BIOLASE that is recorded on the company's balance sheet. Investors also form their own opinion of BIOLASE's value that differs from its market value or its book value, called intrinsic value, which is BIOLASE's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BIOLASE's market value can be influenced by many factors that don't directly affect BIOLASE's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BIOLASE's value and its price as these two are different measures arrived at by different means. Investors typically determine if BIOLASE is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BIOLASE's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.